215 related articles for article (PubMed ID: 35110681)
1. HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin.
Biondini M; Kiepas A; El-Houjeiri L; Annis MG; Hsu BE; Fortier AM; Morin G; Martina JA; Sirois I; Aguilar-Mahecha A; Gruosso T; McGuirk S; Rose AAN; Tokat UM; Johnson RM; Sahin O; Bareke E; St-Pierre J; Park M; Basik M; Majewski J; Puertollano R; Pause A; Huang S; Keler T; Siegel PM
Oncogene; 2022 Mar; 41(12):1701-1717. PubMed ID: 35110681
[TBL] [Abstract][Full Text] [Related]
2. EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.
Yardley DA; Weaver R; Melisko ME; Saleh MN; Arena FP; Forero A; Cigler T; Stopeck A; Citrin D; Oliff I; Bechhold R; Loutfi R; Garcia AA; Cruickshank S; Crowley E; Green J; Hawthorne T; Yellin MJ; Davis TA; Vahdat LT
J Clin Oncol; 2015 May; 33(14):1609-19. PubMed ID: 25847941
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.
Bendell J; Saleh M; Rose AA; Siegel PM; Hart L; Sirpal S; Jones S; Green J; Crowley E; Simantov R; Keler T; Davis T; Vahdat L
J Clin Oncol; 2014 Nov; 32(32):3619-25. PubMed ID: 25267761
[TBL] [Abstract][Full Text] [Related]
4. Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.
Roth M; Barris DM; Piperdi S; Kuo V; Everts S; Geller D; Houghton P; Kolb EA; Hawthorne T; Gill J; Gorlick R
Pediatr Blood Cancer; 2016 Jan; 63(1):32-8. PubMed ID: 26305408
[TBL] [Abstract][Full Text] [Related]
5. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.
Kolb EA; Gorlick R; Billups CA; Hawthorne T; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2014 Oct; 61(10):1816-21. PubMed ID: 24912408
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
Ott PA; Pavlick AC; Johnson DB; Hart LL; Infante JR; Luke JJ; Lutzky J; Rothschild NE; Spitler LE; Cowey CL; Alizadeh AR; Salama AK; He Y; Hawthorne TR; Bagley RG; Zhang J; Turner CD; Hamid O
Cancer; 2019 Apr; 125(7):1113-1123. PubMed ID: 30690710
[TBL] [Abstract][Full Text] [Related]
7. Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer.
Rose AAN; Biondini M; Curiel R; Siegel PM
Pharmacol Ther; 2017 Nov; 179():127-141. PubMed ID: 28546082
[TBL] [Abstract][Full Text] [Related]
8. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.
Rose AA; Grosset AA; Dong Z; Russo C; Macdonald PA; Bertos NR; St-Pierre Y; Simantov R; Hallett M; Park M; Gaboury L; Siegel PM
Clin Cancer Res; 2010 Apr; 16(7):2147-56. PubMed ID: 20215530
[TBL] [Abstract][Full Text] [Related]
9. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
Naumovski L; Junutula JR
Curr Opin Mol Ther; 2010 Apr; 12(2):248-57. PubMed ID: 20373269
[TBL] [Abstract][Full Text] [Related]
10. ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer.
Li Z; Belitzky E; Blaha O; Cavaliere A; Katz SR; Aboian M; Melegari L; Rajabimoghadam K; Kurpiewski S; Zhu X; Marquez-Nostra B
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900378
[TBL] [Abstract][Full Text] [Related]
11. Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent.
Marquez-Nostra BV; Lee S; Laforest R; Vitale L; Nie X; Hyrc K; Keler T; Hawthorne T; Hoog J; Li S; Dehdashti F; Ma CX; Lapi SE
Oncotarget; 2017 Nov; 8(61):104303-104314. PubMed ID: 29262642
[TBL] [Abstract][Full Text] [Related]
12. Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE).
Vaklavas C; Forero A
BioDrugs; 2014 Jun; 28(3):253-63. PubMed ID: 24496926
[TBL] [Abstract][Full Text] [Related]
13. Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer.
Maric G; Rose AA; Annis MG; Siegel PM
Onco Targets Ther; 2013; 6():839-52. PubMed ID: 23874106
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.
Ott PA; Hamid O; Pavlick AC; Kluger H; Kim KB; Boasberg PD; Simantov R; Crowley E; Green JA; Hawthorne T; Davis TA; Sznol M; Hwu P
J Clin Oncol; 2014 Nov; 32(32):3659-66. PubMed ID: 25267741
[TBL] [Abstract][Full Text] [Related]
15. MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
Rose AA; Annis MG; Frederick DT; Biondini M; Dong Z; Kwong L; Chin L; Keler T; Hawthorne T; Watson IR; Flaherty KT; Siegel PM
Clin Cancer Res; 2016 Dec; 22(24):6088-6098. PubMed ID: 27515299
[TBL] [Abstract][Full Text] [Related]
16. The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer.
Keir CH; Vahdat LT
Expert Opin Biol Ther; 2012 Feb; 12(2):259-63. PubMed ID: 22229970
[TBL] [Abstract][Full Text] [Related]
17. Expression pattern and prognostic impact of glycoprotein non-metastatic B (GPNMB) in triple-negative breast cancer.
Huang YH; Chu PY; Chen JL; Huang CT; Huang CC; Tsai YF; Wang YL; Lien PJ; Tseng LM; Liu CY
Sci Rep; 2021 Jun; 11(1):12171. PubMed ID: 34108545
[TBL] [Abstract][Full Text] [Related]
18. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study.
Vahdat LT; Schmid P; Forero-Torres A; Blackwell K; Telli ML; Melisko M; Möbus V; Cortes J; Montero AJ; Ma C; Nanda R; Wright GS; He Y; Hawthorne T; Bagley RG; Halim AB; Turner CD; Yardley DA
NPJ Breast Cancer; 2021 May; 7(1):57. PubMed ID: 34016993
[TBL] [Abstract][Full Text] [Related]
19. CCN3/NOV promotes metastasis and tumor progression via GPNMB-induced EGFR activation in triple-negative breast cancer.
Son S; Kim H; Lim H; Lee JH; Lee KM; Shin I
Cell Death Dis; 2023 Feb; 14(2):81. PubMed ID: 36737605
[TBL] [Abstract][Full Text] [Related]
20. The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB.
Okita Y; Kimura M; Xie R; Chen C; Shen LT; Kojima Y; Suzuki H; Muratani M; Saitoh M; Semba K; Heldin CH; Kato M
Sci Signal; 2017 Apr; 10(474):. PubMed ID: 28400538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
